On 1 October 2026, Edwards Lifesciences announced FDA approval for the AUTUS Size-Adjustable Valve for children with congenital heart defects requiring pulmonary valve replacement. The company states it is the first FDA-approved surgical pulmonary valve designed for pediatric anatomy.
The timing challenge in pediatric heart valve replacement
The proper timing for valve replacement in children with congenital heart disease is difficult, explained Michelle Tarver, director of the FDA's medical devices center. Waiting too long risks harm to the child. Intervening too early may require multiple open-heart surgeries as the child grows. Treatment of congenital heart defects can improve blood flow, but patients can also develop significant pulmonary valve insufficiency that weakens or enlarges the right heart chamber, increasing the need for replacement as they grow. Conventional valve tissues from animals harden and deteriorate faster in children, requiring earlier repeat surgeries more often than in adults.
How the valve works and what the study shows
AUTUS is a prospective, single-arm, multicenter study without a comparison group involving children aged 18 months to 16 years. The valve can initially be implanted at just 13 millimeters in diameter, an appropriate size for a toddler or preschooler. Over time it can be enlarged through a minimally invasive transcatheter procedure using a balloon catheter to up to 22 millimeters, comparable to an adult pulmonary valve. The valve leaflets are made of polymer material rather than animal tissue. AUTUS is the first artificial heart valve approved in the United States with polymer leaflets. The approval is based on a study of 62 pediatric patients at 12 U.S. sites. At the six-month follow-up examination, the first 60 patients showed acceptable hemodynamic function and at most mild valve insufficiency. All participants had successful procedures without deaths, blood clots requiring treatment, strokes or other clot-related complications. The primary safety assessment covers 30 days. Data on valve function and repeat AUTUS procedures cover six months.
On uncertain future benefits
Jennifer Romano, a cardiac surgeon at C.S. Mott Children's Hospital, called the valve a potential game changer at the first AUTUS implantation within the Continued Access Study in September. She suggested it might be possible to give a child a valve that could last a lifetime. Study investigator Emile Bacha also sees in AUTUS a new option for long-term care planning for children who might otherwise need multiple surgeries. Edwards discloses that Bacha has received reimbursement from the company for travel and lodging for educational activities. The company specifically identifies expected benefits such as fewer open-heart surgeries as forward-looking, uncertain statements. Patients are expected to be followed for 10 years.
One tool among many
Edwards places the approval within its existing portfolio for congenital heart defects, which also includes SAPIEN 3, the Alterra Adaptive Prestent and pediatric atrial septostomy catheters. Earlier artificial pulmonary valves could be implanted, but typically required a series of surgeries to replace them with larger ones as the child grew. This is precisely the cycle AUTUS is intended to break. The valve gives physicians the option to avoid the operating room far less often, which could improve the quality of life for children and their families.
The study's primary completion was recorded for 24 August 2026. The estimated final completion date is 5 February 2036. The study is expected to include at least one additional year of follow-up after an expansion. According to SPARK program director Kolaleh Eskandanian, a regulatory gap exists in expanding product labeling to additional pediatric age groups. She calls for test methods, open virtual patient cohorts and a pre-agreed plan for product labeling.